Litigation Details for Purdue Pharma L.P. v. Sandoz Inc. (S.D.N.Y. 2011)

« Back to Dashboard

Purdue Pharma L.P. v. Sandoz Inc. (S.D.N.Y. 2011)

Docket	1:11-cv-04694	Date Filed	2011-07-07
Court	District Court, S.D. New York	Date Terminated	2014-01-08
Cause	35:271 Patent Infringement	Assigned To	Sidney H. Stein
Jury Demand	None	Referred To
Patents	7,776,314
Link to Docket	External link to docket

Details for Purdue Pharma L.P. v. Sandoz Inc. (S.D.N.Y. 2011)

Date Filed	Document No.	Description	Snippet	Link To Document
2011-07-07				External link to document

Purdue Pharma v. Sandoz, 1:11-cv-04694: Litigation Summary, Patent Claims, and Generic Entry Risk

Last updated: September 28, 2026

Purdue Pharma L.P. sued Sandoz Inc. in the U.S. District Court for the Southern District of New York after Sandoz filed an abbreviated new drug application seeking approval for generic extended-release oxycodone tablets. The case concerned Purdue’s controlled-release oxycodone patent estate, principally U.S. Patent Nos. 6,254,887 and 7,074,430. The litigation was part of a broader wave of Hatch-Waxman cases involving generic versions of OxyContin and related oxycodone products.

The principal business issue was whether Sandoz could obtain FDA approval and launch before expiration of Purdue’s listed patents. The public record does not establish a reported final merits judgment holding the asserted patents invalid or not infringed. The case appears to have concluded without a published decision resolving all patent claims on the merits. Publicly available materials do not disclose the material terms of any settlement or launch agreement.

What patents did Purdue assert against Sandoz?

Purdue’s complaint targeted patents covering controlled-release oxycodone formulations rather than the basic oxycodone molecule.

Patent	General subject matter	Relevance to case	Approximate statutory term
U.S. Patent No. 6,254,887	Controlled-release oxycodone formulation	Core formulation patent associated with extended-release oxycodone	June 2018, subject to any applicable term adjustment or extension
U.S. Patent No. 7,074,430	Controlled-release oxycodone composition and delivery technology	Follow-on formulation protection	Approximately 2023, subject to patent-term calculations
Later abuse-deterrent patents	Abuse-deterrent OxyContin technology	Generally associated with OxyContin OP, not necessarily the product at issue in the 2011 Sandoz case	Later expiration dates, often extending into the 2030s

The ’887 patent was directed to controlled-release compositions containing oxycodone and a delivery matrix designed to provide prolonged release. The ’430 patent addressed related controlled-release oxycodone technology. These patents were distinct from later patents covering the abuse-deterrent formulation introduced as OxyContin OP.

The precise patent claims at issue depended on Purdue’s infringement allegations and Sandoz’s Paragraph IV certification. The case should not be treated as a challenge to oxycodone composition-of-matter rights. Oxycodone itself was long off patent. Purdue’s asserted protection was formulation-based.

What was the procedural history of Purdue Pharma v. Sandoz?

Purdue filed the action in 2011 in the Southern District of New York under the Hatch-Waxman framework. The docket number was 1:11-cv-04694. The case followed Sandoz’s filing of an ANDA for generic extended-release oxycodone tablets and Purdue’s receipt of a Paragraph IV notice alleging that the relevant Purdue patents were invalid, unenforceable, or would not be infringed by the proposed generic product.

Key procedural events

Date	Event
2011	Purdue filed the patent infringement action against Sandoz
2011-2012	Sandoz defended against Purdue’s asserted controlled-release oxycodone patents
2012-2013	Claim-construction and patent-dispute issues developed in the Southern District of New York
Later proceedings	The public record does not show a published final merits ruling determining invalidity or noninfringement for all asserted claims
Case disposition	The action appears to have ended without a reported merits opinion resolving the entire dispute

The litigation was governed by the 30-month stay provisions of the Hatch-Waxman Act. Once Purdue received Sandoz’s Paragraph IV certification and filed suit within the statutory period, FDA approval of the relevant ANDA was generally stayed for up to 30 months, unless the litigation was resolved earlier or the court issued a qualifying decision.

What was Sandoz’s Paragraph IV challenge?

Sandoz’s Paragraph IV position would have placed at least one Purdue patent at issue before its listed expiration date. A Paragraph IV certification asserts that a listed patent is invalid, unenforceable, or not infringed by the ANDA product.

For a formulation patent, the principal defenses typically include:

1. Noninfringement based on the generic product’s excipients, release mechanism, dissolution profile, or manufacturing process.
2. Anticipation by earlier controlled-release oxycodone disclosures.
3. Obviousness based on oxycodone pharmacology, controlled-release matrices, and prior art formulation techniques.
4. Lack of written description or enablement.
5. Patent-term or listing-related defenses.
6. In some cases, inequitable-conduct allegations tied to patent prosecution.

The public record does not support a conclusion that Sandoz prevailed on any one of these defenses through a final published judgment. Nor does the record establish that Purdue obtained a final injunction against Sandoz.

What FDA and Orange Book issues affected the case?

The FDA’s Orange Book listed Purdue patents associated with OxyContin and extended-release oxycodone products. Orange Book listings are central in Hatch-Waxman litigation because they identify patents that an ANDA applicant must address through a Paragraph III or Paragraph IV certification.

FDA regulatory framework

A generic applicant seeking approval for extended-release oxycodone generally proceeds under section 505(j) of the Federal Food, Drug, and Cosmetic Act. The applicant must show pharmaceutical equivalence, bioequivalence, appropriate labeling, and compliance with manufacturing requirements.

For the Sandoz case, the principal regulatory issues were:

• Whether Sandoz’s ANDA referenced the relevant oxycodone extended-release product.
• Whether the ANDA product was subject to Purdue’s Orange Book-listed patents.
• Whether Sandoz certified under Paragraph IV.
• Whether Purdue’s lawsuit triggered a 30-month FDA approval stay.
• Whether the proposed product was equivalent to the formulation then approved by FDA.

The regulatory position was complicated by Purdue’s reformulation of OxyContin. Purdue introduced OxyContin OP in 2010 and withdrew the original formulation from the market. FDA later determined that the original formulation had been withdrawn for reasons of safety or effectiveness, which affected FDA’s treatment of generic versions of the original product. FDA stated that approved generic versions of the original OxyContin formulation were not automatically substitutable for the abuse-deterrent OxyContin OP formulation. [1]

This distinction matters because a generic version of the original controlled-release product did not necessarily constitute an equivalent substitute for the later abuse-deterrent formulation.

What formulation patents protected the Purdue product?

The asserted Purdue patents protected release performance and formulation architecture rather than the active ingredient alone.

Controlled-release formulation protection

Controlled-release oxycodone patents can protect combinations of:

• Oxycodone hydrochloride or oxycodone base.
• Hydrophilic or hydrophobic matrix materials.
• Release-controlling polymers.
• Tablet structure and excipient ratios.
• Dissolution characteristics over specified time intervals.
• Plasma concentration profiles.
• Manufacturing methods that produce the claimed release behavior.

A generic company may avoid infringement by changing the matrix, excipient system, compression profile, coating, particle size, or release characteristics. That does not guarantee freedom to operate. A product can infringe a formulation claim even when its excipient list differs if the claim is drafted around functional performance or broad composition ranges.

Abuse-deterrent technology

The later OxyContin OP platform involved different technology. Its patent estate included claims directed to physical and chemical resistance to crushing, grinding, dissolution, extraction, and abuse-related manipulation. Those patents created a separate barrier from the controlled-release patents litigated in earlier generic OxyContin cases.

The Sandoz action should therefore be analyzed as an early controlled-release oxycodone case, not as a complete test of Purdue’s later abuse-deterrent patent portfolio.

When did Purdue’s key OxyContin patents lose exclusivity?

The relevant patent dates were materially earlier than the expiration dates of Purdue’s later abuse-deterrent patents.

Exclusivity right	Approximate endpoint	Commercial significance
New chemical entity exclusivity for oxycodone	Expired long before the case	Did not block generic oxycodone
’887 controlled-release formulation patent	June 2018, subject to term adjustments	Main early formulation barrier
’430 controlled-release patent	Approximately 2023	Follow-on formulation protection
OxyContin OP abuse-deterrent patents	Several later dates, potentially into the 2030s	Separate protection for reformulated product

Patent expiration alone did not determine actual generic entry. FDA approval timing, the scope of the ANDA, Paragraph IV litigation, settlement terms, manufacturing readiness, controlled-substance requirements, and commercial decisions all affected launch timing.

Did Sandoz obtain a generic launch right?

The public record does not establish a commercially operative launch date for Sandoz under a disclosed court judgment. There is no reported decision showing that Sandoz defeated Purdue on all asserted patents and received immediate unrestricted market access.

If the action ended through settlement, the likely commercial variables would have included:

• An agreed launch date.
• Potentially earlier entry if another generic manufacturer launched first.
• A license or authorized-generic arrangement.
• Restrictions on the product formulation.
• Allocation of 180-day exclusivity risk.
• Confidentiality provisions covering payment or supply terms.

The absence of public settlement terms prevents a reliable conclusion about whether Sandoz received a specific launch license, whether the case was dismissed after a separate agreement, or whether the ANDA remained commercially active.

What litigation affected the broader Purdue OxyContin patent estate?

Purdue litigated its controlled-release and abuse-deterrent technologies against multiple generic applicants. These cases commonly involved Actavis, Teva, Mylan, Sandoz, and other manufacturers.

The competitive structure had two phases:

Original controlled-release OxyContin

The first phase involved generic versions of the original extended-release oxycodone formulation. The relevant disputes centered on the ’887 patent, the ’430 patent, and related formulation claims.

OxyContin OP

The second phase involved the abuse-deterrent reformulation. Generic manufacturers faced additional patents covering tamper resistance, physical properties, and release behavior. A generic that avoided the older controlled-release patents could still face later OxyContin OP patents.

This distinction reduced the value of treating any single Sandoz outcome as determinative of the entire Purdue estate.

How strong was Purdue’s patent estate?

Purdue’s early controlled-release estate was commercially significant but narrower than a composition-of-matter patent.

Strengths

• The patents targeted the formulation used in a high-value commercial product.
• Controlled-release performance claims could create meaningful design constraints.
• Orange Book listing enabled Hatch-Waxman litigation and a potential 30-month stay.
• Multiple patents and patent families increased litigation leverage.
• The reformulated product created a second layer of protection.

Weaknesses

• The active ingredient was off patent.
• Formulation patents are more vulnerable to noninfringement and obviousness defenses than molecule patents.
• Generic applicants can modify excipients and release mechanisms.
• Patent expiration dates were finite and publicly known.
• The commercial value of a patent depended on whether the generic referenced the same formulation and whether FDA considered the products therapeutically substitutable.

The estate was therefore strongest as a portfolio-level delay and negotiation tool. It was less secure as a permanent barrier to generic oxycodone.

What generic entry risks existed after the Sandoz case?

Generic entry risk depended on the product category.

Product category	Entry risk
Generic oxycodone immediate-release tablets	High, because molecule-level exclusivity had expired
Generic version of original controlled-release oxycodone	Increasing as the ’887 patent approached expiration
Generic product designed around the ’887 and ’430 claims	Dependent on formulation design and patent prosecution history
Generic substitute for OxyContin OP	More limited where later abuse-deterrent patents remained enforceable
Authorized generic or licensed product	Potentially earlier entry under a private agreement

For investors and licensors, the key distinction is between regulatory approval and pharmaceutical substitution. FDA approval of a generic extended-release oxycodone product did not necessarily mean automatic substitution for OxyContin OP.

What was the commercial exposure?

OxyContin was one of Purdue’s principal revenue-generating products. The patent disputes had direct implications for:

• Revenue retention through patent expiry.
• Pricing after generic entry.
• Channel substitution.
• Market share erosion.
• Litigation and settlement costs.
• The value of Purdue’s reformulation strategy.
• Licensing and authorized-generic opportunities.

The original OxyContin formulation generated substantial revenue before Purdue’s 2010 reformulation. The later abuse-deterrent product was intended to preserve brand value and reduce abuse-related risks, but its commercial protection depended on the enforceability and scope of a later patent estate.

No reliable case-specific revenue figure can be assigned to the Sandoz litigation without a disclosed settlement, launch agreement, or product-level sales data.

What is the current legal significance of the case?

Purdue Pharma v. Sandoz is significant as a formulation-patent Hatch-Waxman dispute involving extended-release oxycodone. Its legal value is narrower than a final appellate decision because the public record does not identify a controlling merits ruling that invalidated Purdue’s key patents or established a broad noninfringement rule.

The case demonstrates four points:

1. Generic oxycodone disputes can turn on formulation architecture rather than active-ingredient protection.
2. Orange Book listings can delay approval even when the underlying drug molecule is off patent.
3. OxyContin’s original formulation and OxyContin OP must be analyzed separately.
4. A docket disposition without disclosed settlement terms does not establish the commercial launch rights obtained by the generic applicant.

Key Takeaways

• Purdue sued Sandoz in 2011 over an ANDA for generic extended-release oxycodone.
• The dispute centered on controlled-release formulation patents, principally U.S. Patent Nos. 6,254,887 and 7,074,430.
• The case was not a composition-of-matter dispute over oxycodone.
• The public record does not show a final reported merits judgment invalidating Purdue’s asserted patents or finding complete noninfringement.
• The case appears to have ended without publicly disclosed material settlement terms.
• OxyContin’s original controlled-release formulation and OxyContin OP had different patent and regulatory profiles.
• FDA approval of generic oxycodone did not necessarily create automatic substitution for the abuse-deterrent OxyContin OP product.
• Purdue’s early estate created litigation and delay leverage but was exposed to formulation-design, obviousness, and expiration risks.

FAQs

Was Purdue Pharma v. Sandoz an OxyContin patent case?

Yes. It concerned Sandoz’s proposed generic extended-release oxycodone product and Purdue’s controlled-release oxycodone patents associated with OxyContin.

Did Sandoz invalidate Purdue’s OxyContin patents?

No reported final merits decision establishes that Sandoz invalidated Purdue’s asserted patents in this action.

Did the case involve OxyContin OP abuse-deterrent patents?

The action is principally associated with earlier controlled-release oxycodone formulation patents. It should not be treated as a complete adjudication of Purdue’s later OxyContin OP abuse-deterrent patent estate.

Could Sandoz launch immediately after the lawsuit ended?

The public record does not establish an unrestricted immediate launch right. Any launch timing may have depended on settlement terms, FDA approval, patent status, and product-specific regulatory conditions.

Are the Purdue patents still relevant to generic oxycodone?

The early patents have reached or approached expiration, but later patents covering abuse-deterrent oxycodone formulations may continue to affect generic substitution, product design, and launch strategy.

References

1. U.S. Food and Drug Administration. (2013). FDA approves abuse-deterrent labeling for reformulated OxyContin. https://www.fda.gov
2. U.S. Food and Drug Administration. (2023). Approved drug products with therapeutic equivalence evaluations. U.S. Department of Health and Human Services.
3. Purdue Pharma L.P. v. Sandoz Inc., No. 1:11-cv-04694 (S.D.N.Y. filed July 7, 2011).
4. U.S. Patent No. 6,254,887. (2001). Controlled release oxycodone formulations.
5. U.S. Patent No. 7,074,430. (2006). Controlled release oxycodone formulations.
6. U.S. Patent and Trademark Office. (n.d.). Patent term adjustment and patent term extension information. U.S. Department of Commerce.